IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Åkesson, P.
Right arrow Articles by von Pawel-Rammingen, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Åkesson, P.
Right arrow Articles by von Pawel-Rammingen, U.
Infection and Immunity, January 2006, p. 497-503, Vol. 74, No. 1
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.1.497-503.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

IdeS, a Highly Specific Immunoglobulin G (IgG)-Cleaving Enzyme from Streptococcus pyogenes, Is Inhibited by Specific IgG Antibodies Generated during Infection

Per Åkesson,1,{dagger} Linnea Moritz,2,{dagger} Mikael Truedsson,3 Bertil Christensson,1 and Ulrich von Pawel-Rammingen2*

Department of Clinical Science, Lund University, Lund, Sweden,1 Department of Molecular Biology, Umeå University, Umeå, Sweden,2 Department of Community Medicine, Malmö University Hospital, Lund University, Malmö, Sweden3

Received 13 September 2005/ Accepted 19 October 2005

IdeS, a recently discovered cysteine proteinase secreted by the important human pathogen Streptococcus pyogenes, interferes with phagocytic killing by specifically cleaving the heavy chain of immunoglobulin G. The fact that the enzyme targets one of the key molecules of the adapted immune response raised the question of whether an antibody response against IdeS could inhibit, i.e., neutralize, enzyme activity. Paired acute- and convalescent-phase serum samples from patients with pharyngotonsillitis (n = 10), bacteremia (n = 7), and erysipelas (n = 4) were analyzed. Antibodies with the ability to neutralize IdeS enzymatic activity were already found in two-thirds of acute-phase sera. However, patients who seroconverted to IdeS, in particular patients with pharyngotonsillitis and erysipelas, developed specific antibodies during convalescence with an increased capability to efficiently neutralize the enzymatic activity of IdeS. Also, the presence of neutralizing antibodies decreased the ability of IdeS to mediate bacterial survival in human immune blood. In patients with bacteremia, several acute-phase sera contained neutralizing antibodies, but no correlation was found to severity or outcome of invasive infections. Still, the fact that the human immune response targets the enzymatic activity of IdeS supports the view that the enzyme plays an important role during streptococcal infection.


* Corresponding author. Mailing address: Department of Molecular Biology, Umeå University, 90187 Umeå, Sweden. Phone: 46 90 785 6705. Fax: 46 90 772630. E-mail: ulrich.von-pawel{at}molbiol.umu.se.

Editor: J. N. Weiser

{dagger} The first two authors contributed equally to this work.


Infection and Immunity, January 2006, p. 497-503, Vol. 74, No. 1
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.1.497-503.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2006 by the American Society for Microbiology. All rights reserved.